AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 23 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Immunity against intracranial T9 gliomas was conferred by treatment of rats with live cloned T9-C2 glioma cells that expressed macrophage colony-stimulating factor (mM-CSF), according to a report by researchers from the U.S.
Yijun Chen and colleagues at the University of California-Irvine, and California State University and the Veterans Affairs Medical Center in Long Beach, found that control T9 glioma cells formed subcutaneous tumors in rats but cloned T9-C2 cells expressing mM-CSF or Bcl2 did not.
The mechanism of protection conferred by immunization using T9-C2 cells involved vacuolization of tumor cells mitochondria and endoplasmic reticula, which caused cell swelling and death within 24 hours. Cytokines produced by T9 and T9-C2 cells caused granulocyte accumulation at the tumor injection site. Macrophages also interacted with the tumor cells, causing death by methods other than phagocytosis (Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"-induced pathway that promotes systemic immunity against intracranial T9 gliomas. Blood, 2002;100(4):1373-1380).
The involvement of both macrophages and polymorphonuclear (PMN) leukocytes was demonstrated by treating athymic rats with antibodies against PMN leukocytes and/or macrophages. Only 40% of the rats given one of the antibodies developed T9-C2 tumors while 80% of the rats given both antibodies developed tumors. Rats able to ...
Source: HighBeam Research, Cloned T9 cells protect against intracranial glioma tumors.